Gateway for:

Member Countries

Monoclonal and Recombinant Antibodies for the Variola Virus

#1986


Development of Monoclonal and Recombinant Antibodies for Therapy and Diagnostics of Variola Virus and other Orthopoxviruses with Human Pathogenicity

Tech Area / Field

  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
  • MED-DID/Diagnostics & Devices/Medicine
  • BIO-MIB/Microbiology/Biotechnology
  • MED-VAC/Vaccines/Medicine

Status
3 Approved without Funding

Registration date
05.09.2000

Leading Institute
State Research Center of Virology and Biotechnology VECTOR, Russia, Novosibirsk reg., Koltsovo

Supporting institutes

  • Research Institute of Viral Preparations, Russia, Moscow

Collaborators

  • CNRS / Institut de Biologie Structurale et Microbiologie, France, Marseille

Project summary

The main goal of the Project entitled «Development of monoclonal and recombinant antibodies for the purposes of therapy and diagnostics of variola virus and other orthopoxviruses with a pathogenic role in human pathology» is to look into an opportunity of developing the panels of antibodies with a virus neutralizing or protective action against variola virus (VAR). It is expected to develop monoclonal antibodies (MCA), recombinant antibodies against VAR antigens, and test antibodies against other orthopoxviruses for interactions with VAR in order to reveal cross-reactive and antigen-like proteins among orthopoxviruses:

– in association with identification of antibodies promising for prevention and treatment of diseases caused by orthopoxviruses, including possible effects of vaccinations;

– in search of antibodies providing adequate identification of variola virus and other pathogenic orthopoxviruses using the easiest immunological tests.

Development of these trends in research will lay grounds for developing immunological research for the assessment of the immune response of the organism to the antigens of VAR and other orthopoxviruses, provide the researchers with standard antibody preparations, allow VAR proteins inducing neutralizing and protective antibodies to be identified. Specific features of the hybridoma and molecular-biological techniques will allow antibodies collections to be created that might be the sources of new batches of antibodies for as long as deemed necessary without the production of virus antigens or the use of pathogenic strains of orthopoxviruses. This will allow the researchers to be provided with standard sets of antibodies for express diagnostics of and protection against this infection as the need arises and in the quickest manner possible.

The Project will include the following stages of research:

1. Developing monoclonal antibodies against structural proteins of VAR and other orthopoxviruses.


2. Studying MCA against other orthopoxviruses for their interaction with VAR antigens.
3. Creating and keeping a collection of hybridomas to the variola virus and other orthopoxviruses.
4. Developing diagnostic and neutralizing recombinant antibodies to VAR and other orthopoxviruses using combinatorial phage libraries.
5. Assessing protective and therapeutic effects of the monoclonal and recombinant antibodies on model animals.

Upon completion of the above stages, the following successful events are expected: obtainment of the purified and inactivated VAR antigen; development of panels of hybridomas secreting monoclonal antibodies (MCA) against the variola virus and other orthopoxviruses; acquisition of data on virus neutralizing and protective action of MCA with respect to the variola virus on model test systems (animals, primary human and animal cell cultures); production of standard preparations of monoclonal antibodies; creating a long-term collection of hybridomas secreting monoclonal antibodies against the variola virus; formation of a panel of recombinant antibodies against various strains of VAR and other orthopoxviruses. The collection of monoclonal and recombinant antibodies with their protective and virus neutralizing actions with respect to VAR will allow the Project countries to be supplied with standard immunobiological preparation.


Back

The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.

 

ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.

Promotional Material

Значимы проект

See ISTC's new Promotional video view